Pharma & Healthcare
Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Research Report 2026
- Mar 17, 26
- ID: 738327
- Pages: 94
- Figures: 96
- Views: 1
This report delivers a comprehensive overview of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding GLP-1 Agonists for the Treatment of both Diabetes and Obesity. The GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist GLP-1 Agonists for the Treatment of both Diabetes and Obesity manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Novo Nordisk
Eli Lilly
Segment by Type
Semaglutide
Liraglutide
Tirzepatide
Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for GLP-1 Agonists for the Treatment of both Diabetes and Obesity companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
The report segments the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist GLP-1 Agonists for the Treatment of both Diabetes and Obesity manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Novo Nordisk
Eli Lilly
Segment by Type
Semaglutide
Liraglutide
Tirzepatide
Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for GLP-1 Agonists for the Treatment of both Diabetes and Obesity companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Semaglutide
1.2.3 Liraglutide
1.2.4 Tirzepatide
1.3 Market by Application
1.3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Perspective (2021–2032)
2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Growth Trends by Region
2.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Region (2021–2026)
2.2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Region (2027–2032)
2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Dynamics
2.3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends
2.3.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
2.3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Challenges
2.3.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue
3.1.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue (2021–2026)
3.1.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Players (2021–2026)
3.2 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue
3.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Concentration Ratio
3.4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue in 2025
3.5 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity Head Offices and Areas Served
3.6 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Products and Applications
3.7 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Type
4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Type (2021–2026)
4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Type (2027–2032)
5 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Application
5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Application (2021–2026)
5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
6.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)
6.4 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
7.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)
7.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
8.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021–2026)
8.4 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
9.2 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)
9.4 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
10.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)
10.4 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Details
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Introduction
11.1.4 Novo Nordisk Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)
11.1.5 Novo Nordisk Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Introduction
11.2.4 Eli Lilly Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)
11.2.5 Eli Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Semaglutide
1.2.3 Liraglutide
1.2.4 Tirzepatide
1.3 Market by Application
1.3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Perspective (2021–2032)
2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Growth Trends by Region
2.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Region (2021–2026)
2.2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Region (2027–2032)
2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Dynamics
2.3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends
2.3.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
2.3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Challenges
2.3.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue
3.1.1 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Revenue (2021–2026)
3.1.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Players (2021–2026)
3.2 Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue
3.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Concentration Ratio
3.4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue in 2025
3.5 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity Head Offices and Areas Served
3.6 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Products and Applications
3.7 Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Type
4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Type (2021–2026)
4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Type (2027–2032)
5 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Breakdown Data by Application
5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size by Application (2021–2026)
5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
6.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)
6.4 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
7.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)
7.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
8.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021–2026)
8.4 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
9.2 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)
9.4 Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021–2032)
10.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021–2026)
10.4 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Details
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Introduction
11.1.4 Novo Nordisk Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)
11.1.5 Novo Nordisk Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Introduction
11.2.4 Eli Lilly Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)
11.2.5 Eli Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Semaglutide
Table 3. Key Players of Liraglutide
Table 4. Key Players of Tirzepatide
Table 5. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million), 2021–2026
Table 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2021–2026)
Table 9. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2027–2032)
Table 11. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Trends
Table 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
Table 13. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Challenges
Table 14. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
Table 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Players (US$ Million), 2021–2026
Table 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Players (2021–2026)
Table 17. Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Tier (Tier 1, Tier 2, and Tier 3), based on GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, 2025
Table 18. Ranking of Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Headquarters and Area Served
Table 21. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Products and Applications
Table 22. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (US$ Million), 2021–2026
Table 25. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2021–2026)
Table 26. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2027–2032)
Table 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (US$ Million), 2021–2026
Table 29. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2021–2026)
Table 30. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2027–2032)
Table 32. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026
Table 34. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032
Table 35. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026
Table 37. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032
Table 47. Novo Nordisk Company Details
Table 48. Novo Nordisk Business Overview
Table 49. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product
Table 50. Novo Nordisk Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (US$ Million), 2021–2026
Table 51. Novo Nordisk Recent Development
Table 52. Eli Lilly Company Details
Table 53. Eli Lilly Business Overview
Table 54. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product
Table 55. Eli Lilly Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (US$ Million), 2021–2026
Table 56. Eli Lilly Recent Development
Table 57. Research Programs/Design for This Report
Table 58. Key Data Information from Secondary Sources
Table 59. Key Data Information from Primary Sources
Table 60. Authors List of This Report
List of Figures
Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Picture
Figure 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type: 2025 vs 2032
Figure 4. Semaglutide Features
Figure 5. Liraglutide Features
Figure 6. Tirzepatide Features
Figure 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (US$ Million), 2021–2032
Figure 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application: 2025 vs 2032
Figure 9. Hospital and Clinic Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Other Case Studies
Figure 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Report Years Considered
Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region: 2025 vs 2032
Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Players in 2025
Figure 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue in 2025
Figure 19. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)
Figure 21. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)
Figure 25. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2021–2032)
Figure 33. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)
Figure 41. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)
Figure 45. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Novo Nordisk Revenue Growth Rate in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)
Figure 49. Eli Lilly Revenue Growth Rate in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Table 1. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Semaglutide
Table 3. Key Players of Liraglutide
Table 4. Key Players of Tirzepatide
Table 5. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million), 2021–2026
Table 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2021–2026)
Table 9. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2027–2032)
Table 11. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Trends
Table 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
Table 13. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Challenges
Table 14. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
Table 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Players (US$ Million), 2021–2026
Table 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Players (2021–2026)
Table 17. Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players by Tier (Tier 1, Tier 2, and Tier 3), based on GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, 2025
Table 18. Ranking of Global Top GLP-1 Agonists for the Treatment of both Diabetes and Obesity Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Headquarters and Area Served
Table 21. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Products and Applications
Table 22. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (US$ Million), 2021–2026
Table 25. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2021–2026)
Table 26. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2027–2032)
Table 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (US$ Million), 2021–2026
Table 29. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2021–2026)
Table 30. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2027–2032)
Table 32. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026
Table 34. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032
Table 35. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026
Table 37. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (US$ Million), 2027–2032
Table 47. Novo Nordisk Company Details
Table 48. Novo Nordisk Business Overview
Table 49. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product
Table 50. Novo Nordisk Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (US$ Million), 2021–2026
Table 51. Novo Nordisk Recent Development
Table 52. Eli Lilly Company Details
Table 53. Eli Lilly Business Overview
Table 54. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product
Table 55. Eli Lilly Revenue in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (US$ Million), 2021–2026
Table 56. Eli Lilly Recent Development
Table 57. Research Programs/Design for This Report
Table 58. Key Data Information from Secondary Sources
Table 59. Key Data Information from Primary Sources
Table 60. Authors List of This Report
List of Figures
Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Picture
Figure 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type: 2025 vs 2032
Figure 4. Semaglutide Features
Figure 5. Liraglutide Features
Figure 6. Tirzepatide Features
Figure 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (US$ Million), 2021–2032
Figure 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application: 2025 vs 2032
Figure 9. Hospital and Clinic Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Other Case Studies
Figure 12. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Report Years Considered
Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region: 2025 vs 2032
Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Players in 2025
Figure 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue in 2025
Figure 19. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)
Figure 21. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)
Figure 25. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2021–2032)
Figure 33. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)
Figure 41. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021–2032)
Figure 45. Israel GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Novo Nordisk Revenue Growth Rate in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)
Figure 49. Eli Lilly Revenue Growth Rate in GLP-1 Agonists for the Treatment of both Diabetes and Obesity Business (2021–2026)
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232